Why a Tinted Sunscreen Might Actually Be Better Than Your Average SPF
Mineral versus chemical, cream versus oil, ideal SPF filter—there are many factors to consider when shopping for the best sunscreen. But of all the questions posed, the latest discourse has been around tinted versus un-tinted, which is better?
Vogue's Favorite Tinted Sunscreens
'I wouldn't say that tinted sunscreens are overall better than traditional sunscreens (as a dermatologist, getting patients to regularly apply any sunscreen is a win!), but I will say that tinted sunscreens are better for certain skin needs than other kinds of sunscreens,' board-certified dermatologist Dr. Corey L. Hartman tells Vogue, and fellow dermatologist Dr. Elyse Love agrees. 'Tinted sunscreens are similar to their un-tinted counterparts from an SPF filter perspective, but they contain added pigment in the formula—typically composed of iron oxide and pigmentary titanium dioxide,' which she says provides visible light protection. 'This is particularly relevant for darker skin tones. Visible light can cause and worsen pigmentation in darker skin tones.'
Basically, as nurse practitioner Catie Boucher explains, the iron oxides that give the tint, act as a physical barrier on the skin to reflect and scatter visible light. 'More specifically, iron oxides also shield against another component of visible light called blue light,' she says. 'We know that blue light can stimulate pigment cells known as melanocytes, which can lead to pigmentation disorders such as melasma. When it comes to treating and preventing pigment disorders, it takes a village. Choosing a tinted sunscreen provides another layer of protection that is much needed.' So, anyone with deeper skin tones or pigmentation prone (be it melasma, post-acne scarring, or sun spots, should consider working in a tinted sunscreen instead. And there's a wealth of evidence to support it, too. Hartman cites a 2022 research study, for example, that demonstrates using tinted sunscreen as an effective strategy in reducing melasma.
Naturally, narrow, 'universal' shade ranges pose a challenge to finding an appropriate tint; a limitation and an outdated norm the industry is finally moving away from. In recent years, thoughtful reformulations of the best tinted sunscreens have coincided with more expansive offerings, taking into account varied undertones and shades from fair to deep. Merit's latest, The Uniform, features 15 shades, mirroring those of its beloved The Minimalist complexion stick. It's a similar story across the pond for Beauty of Joseon's tinted serum, offering 12 shades in an impressive range. Even La Roche-Posay recently introduced three new shades to its classic Anthelios Tinted Sunscreen SPF 40+—now offering Medium, Medium Deep, and Deep alongside a separate universal tint. And for those more interested in a glow, options by iNNBeauty Project and Kosas work to illuminate and bronze the complexion, adding a radiant gleam in lieu of a traditional complexion-evening tint.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
National Research Solidifies Dividend Amid Insider Buying and Contract Growth
National Research Corporation (NASDAQ:NRC) is one of the 10 low risk dividend paying stocks for June 2025. The company has reported a sequential increase in total recurring contract value, which is followed by a notable change in insider activity. A healthcare professional using a digital device to provide a health risk assessment to a patient. National Research Corporation (NASDAQ:NRC), carrying on business operations as NRC Health, is a healthcare organization based in Nebraska. With their subscription-based solutions, the company offers analytics and insights that enable healthcare organizations to improve patient and employee experience. The focus of the solutions is aimed at various aspects of the company's operations, including patient satisfaction, staff retention, and brand perception. National Research Corporation (NASDAQ:NRC) reported its Q1 results for 2025, earlier this May, in which it reported a sequential increase in total recurring contract value. With this growth, the company recorded a notable milestone in its revenue growth strategy. Following the announcement, on May 12, 2025, Patrick Beans, a significant shareholder, acquired an additional 2,500 shares of the company's common stock in a transaction valued at $33,973. The company offers a dividend yield of 2.90%, with a beta of 0.39, signaling its limited volatility to the market changes. The ex-dividend date is June 27, 2025, and investors seeking to benefit from the next payout should purchase the stock before the date. While we acknowledge the potential of NRC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
'I Used To Dread The Gym With My Chronic Illness. These 3 Moves Transformed My Strength.'
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Back in 2020, at 32 years old, I had a stroke. As a result, I was bedridden for weeks and ultimately diagnosed with functional neurological disorder (FND), a chronic condition caused by changes in how the brain networks work, leading to unexpected and temporary paralysis of the limbs, seizures, and speech difficulties. My FND symptoms can last anywhere from hours to weeks at a time, and over the last five years since my diagnosis, I've frequently had to use a wheelchair. There's not necessarily a specific trigger behind my FND symptoms, but I also struggle with endometriosis (when the inner lining of the uterus grows outside the uterus) and adenomyosis (when tissue from the lining of the uterus grows into the muscular wall of the uterus); for me, I've noticed that when symptoms of one condition worsen, the other condition usually isn't far behind. Exercise isn't always accessible with a disabled body, and I don't have a ton of support from doctors, but I've found incredible workout inspiration on Instagram. Accounts like @micagetsit and @k.a.t.r.i.n.a_0fficial share exercise resources and modifications to traditional movements, along with inclusive accountability tips. For example, if running or jumping isn't accessible to me, I've learned to march in place. Every week looks different depending on how I physically feel, but I try to move my body twice a week. I still get residual effects of paralysis in my legs, so lower body strength is a priority. I typically do three moves per session at the gym, with three sets of 10 reps. Hip thrusts, hamstring curls, and leg presses are the staples in my routine to improve my lower body strength and stability, and I aim to slightly increase weight with each set. Most recently, I was able to do 10 reps of a 35-kilogram leg press (roughly 77 pounds). Gentle pilates stretching and core exercises are also part of my routine to help with overall mobility and stability. On top of that, I walk outside as much as I'm able and love exploring different types of movements. For me, exercise isn't just about being in the gym and cranking out reps. It's about being grateful for my body, honoring its limitations, and moving in any way that feels good. Working out has absolutely improved my endurance and made everyday tasks like gardening and going up the stairs easier, but I also take recovery very seriously. The steam room and sauna are my happy place—it's where I stretch, relax, and focus on controlled breathwork. Muscle spasms are a common symptom of FND, but the steam room and sauna have tremendously helped with my pain management. I also regularly use a vibration plate, which helps me alleviate muscular tension and boost circulation when I feel stiff or sore. That said, despite my best efforts to feel good and strong, there are days or weeks when my chronic conditions require me to completely rest, and that's okay. I understand my body's limitations and listen when I need to scale back. I also experiment with herbal medicine for symptom management and pain relief. I've been on and off various medications since my stroke, but they tend to make me sick and cause an unhealthy amount of weight loss. However, as a certified herbalist and aromatherapist, I take a variety of natural supplements and herbs to help with my symptom management and pain relief. Capsules supplements are typically my go-to, but I also love infusing a hot bath with herbal essential oils. As someone who struggles with anxiety and depression, lemon balm and St. John's wort have worked well for my mood management when I'm feeling on edge. I've also had success with peppermint and castor oil to help manage cramps caused by my endometriosis and adenomyosis. First, I constantly remind myself that we only have one life, and I never give up. This might sound cliché, but having a stroke at such a young age taught me that life is short. I've accepted that I'm not the same person I was prior to my stroke in 2020, but my mission is to live my life to the fullest. Instead of focusing on the negative and dwelling on what I can't do, I learned to prioritize the positive and celebrate what I can. I owe it to myself to live the life I want to live. I'll always have a chronic disease, but I will not let it define me—it's just one part of my story. My journey has been far from easy, and I know there will be future ups and downs, but I'm so proud of how far I've come. If there is one thing I've learned in the last five years since my stroke, it's that giving up is not an option. When things get hard, I focus on taking one day or one step at a time. Why? Because small steps often lead to big wins. Secondly, if I feel down about myself or my training, I try to take a moment to appreciate that my body is resilient, and I'm capable of progress. Living with chronic health conditions is hard and scary, but I'm so proud of my body for overcoming the challenges. Doctors didn't think I would be able to walk again after my stroke, but through all the pain, uncertainty, and hospitalizations, here I am at 37, not only walking, but also lifting heavy weights. My strength journey is full of setbacks since my FND flares still unexpectedly happen, but I've learned that progress in and out of the gym is not always linear. Progress is about listening to my body, honoring its current ability, and celebrating its resilience. My body may look and feel different than it once did, but I am still strong, capable, and very committed to living the life I want to live. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Medscape
44 minutes ago
- Medscape
Sclerosing Mesenteritis: Update on Rare GI Disease
The American Gastroenterological Association (AGA) has issued an updated pragmatic review on sclerosing mesenteritis (SM). Published in Clinical Gastroenterology and Hepatology, the update evaluates available evidence for diagnosis and treatment and examines opportunities for future research in SM, previously known by such names as misty mesentery, mesenteric panniculitis, and inflammatory pseudotumor. Led by Mark T. Worthington, MD, a professor of medicine in the Division of Gastroenterology and Hepatology at the University of Virginia in Charlottesville, Virginia, an expert AGA panel described SM as an uncommon benign idiopathic autoimmune disease of the mesenteric fat. Although of poorly understood etiology, gastroenterologists need to be prepared to diagnose it. 'CT radiologists increasingly are reporting SM and related lesions, such as misty mesentery,' Worthington told Medscape Medical News . 'We are also seeing new SM cases caused by immune checkpoint inhibitors in cancer treatment, and the oncologists ask us to manage this because it interferes with the treatment of the underlying malignancy. Those are often readily treated because we catch them so early.' Metabolic syndrome and associated conditions increase the risk for SM, as does aging. The recent changes are intended to help clinicians predict disease activity and the need for other testing or treatment. 'For instance, most cases are indolent and do not require aggressive treatment — often no treatment at all — but for those that are aggressive, we want the clinician to be able to identify those and make sure the treatment is appropriate. The aggressive cases may warrant tertiary referral,' Worthington said. 'A secondary cancer is a possibility in this condition, so drawing from the SM radiology studies, we try to help the clinician decide who needs other testing, such as PET-CT or biopsy, and who can be monitored.' As many as 60% of cases are asymptomatic, requiring no treatment. Abdominal pain is the most frequent symptom and its location on clinical examination should correspond to the SM lesion on imaging. Treatment involves anti-inflammatory medications tailored to disease severity and clinical response. No biopsy is not necessary if the lesion meets three of the five CT criteria reported by B. Coulier and has no features of more aggressive disease or malignancy. Although some have suggested that SM may be a paraneoplastic syndrome, current evidence does not support this. SM needs to be differentiated from other diagnoses such as non-Hodgkin's lymphoma, peritoneal carcinomatosis, and mesenteric fibromatosis. 'There are now CT guidelines for who actually has SM, who needs a biopsy or a PET-CT to rule-out malignancy, and who doesn't,' said Worthington. 'Radiologists do not always use the Coulier criteria for diagnosis, but often they will with encouragement. From this review, a GI clinician should be able to identify SM on CT.' Epidemiologically, retrospective CT studies have reported a frequency of 0.6%-1.1%, the panelists noted. And while demographic data are limited, a large early case series reported that SM patients had a mean age of 55 years and more likely to be men and of White race. Patients with SM do not have a higher prevalence of autoimmunity in general, but may have increased rates of metabolic syndrome, obesity, coronary artery disease, and urolithiasis, the panelists noted. The update allows room for differences in clinical judgment. 'For instance, a longer or more frequent CT surveillance interval can be justified depending on the patient's findings, and no one should feel locked in by these recommendations,' Worthington said. Medical Therapy Although there is no surgical cure, pharmacologic options are many. These include prednisone, tamoxifen, colchicine, azathioprine, thalidomide, cyclophosphamide, and methotrexate, as well as the biologics rituximab, infliximab and ustekinumab. Current corticosteroid-based therapies often require months to achieve a clinical response, however. Bowel obstruction is managed nonoperatively when feasible, but medically refractory disease may require surgical bypass. Offering his perspective on the guidance but not involved in its formulation, Gastroenterologist Stephen B. Hanauer, MD, a professor of medicine at Northwestern Medicine in Chicago, said, 'The most useful component of the practical review is the algorithm for diagnosis and determination when biopsy or follow-up imaging is reasonable in the absence of evidence.' He stressed that the recommendations are pragmatic rather than evidence-based 'as there are no controlled trials and the presentation is heterogeneous.' Hanauer added that none of the recommended treatments have been shown to impact reduction on imaging. 'Hence, all of the treatments are empiric without biological or imaging endpoints.' In his experience, patients with inflammatory features are the best candidates for immune-directed therapies as reduction in inflammatory markers is a potential endpoint, although no therapies have demonstrated an effect on imaging or progression. 'As an IBD doctor, I favor steroids and azathioprine or anti-TNF directed therapy, but again, there is no evidence beyond reports of symptomatic improvement.' Worthington and colleagues agreed that treatment protocols have developed empirically. 'Future investigation for symptomatic SM should focus on the nature of the inflammatory response, including causative cytokines and other proinflammatory mediators, the goal being targeted therapy with fewer side effects and a more rapid clinical response,' they wrote. Currently, said Worthington, the biggest gaps remain in treatment. 'Even the best studies are small and anecdotal, and we do not know the cytokine or other proinflammatory mediators.' In other comments, Gastroenterologist Eli D. Ehrenpreis, MD, research director, Internal Medicine Residency, at Advocate Lutheran General Hospital in Park Ridge, Illinois, and not involved in the update, found it fell short in several ways, including nomenclature. 'The appropriate term for this condition is mesenteric panniculitis, meaning inflammation of the mesenteric fat, seen histologically on biopsy. The term sclerosing mesenteritis introduces the idea of fibrosis, which is seen in a smaller number of patients, not all,' he told Medscape Medical News . Ehrenpreis also took issue with the inclusion of the cancer drug tamoxifen as the most common treatment used. 'Mesenteric panniculitis, when it does not represent a malignancy, is a benign disease,' he said. 'However, many patients on tamoxifen will experience hormone-related adverse effects such as breast tenderness and hot flashes.' He noted the drug has an FDA Black Box warning for uterine malignancies, pulmonary embolism, and other thromboembolic events, including stroke. Another significant gap, in his view, is the lack of recognition of the psychological effects on patients of the diagnosis. According to Ehrenpreis, more prospective analyses of treatments are needed with objective measures of success including symptom scoring and laboratory testing with erythrocyte sedimentation rate and C-reactive protein. 'And as with many rare diseases, a better understanding of the psychological effects of having a poorly understood disease and management of this challenge is vital to the comprehensive care of the patient with mesenteric panniculitis.' This guidance was supported by the AGA. Worthington reported renumeration from TriCity Surgery Center, Prescott, Ariz. The coauthor Wolf has received renumeration from AbbVie, Align Technology, Alnylam Pharmaceuticals, CVS Health ORP, Dexcom, Exact Sciences, HCA Healthcare, Johnson & Johnson, Eli Lilly, McKesson, Moderna, Regeneron Pharmaceuticals, Sarepta Therapeutics, Seagen, Stryker, and Thermo Fisher Scientific. Crockett has served as a consultant for IngenioRx. Pardi has served as a consultant for Boehringer Ingelheim and received research support from Atlantic, ExeGI Pharma, Rise Therapeutics, Janssen, Pfizer, Seres, Applied Molecular Transport, Takeda Pharmaceuticals, and Vedanta Biosciences. Hanauer and Ehrenpreis had no conflicts of interest relevant to their comments.
